Table 3.
As-observed analysis of CRS, CRM, SRM, and MH in patients with UC and CD after 6 months and 1 year of VDZ therapy.
| Group |
6 mo | 1 y | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CRS | CRM | SRM | MH | CRS | CRM | SRM | MH | ||
| UC | Total | 82.5, 80/97 | 43.3, 42/97 | 26.0, 20/77 | 69.0, 40/58 | 76.0, 38/50 | 58.0, 29/50 | 35.0, 14/40 | 62.2, 23/37 |
| Biologic-naïve | 81.3, 52/64 | 39.1, 25/64 | 28.8, 25/52 | 64.9, 24/37 | 79.4, 27/34 | 55.9, 19/34 | 34.6, 9/26 | 61.5, 16/26 | |
| Biologic-exposed | 84.8, 28/33 | 51.5, 17/33 | 35.0, 14/40 | 76.2, 16/21 | 68.8, 11/16 | 62.5, 10/16 | 35.7, 5/14 | 63.6, 7/11 | |
| CD | Total | 56.0, 47/84 | 51.2, 43/84 | 26.4, 14/53 | 12.0, 3/25 | 57.1, 32/56 | 71.4, 40/56 | 33.3, 11/33 | 30.0, 9/30 |
| Biologic-naïve | 67.4a, 29/43 | 62.8a, 27/43 | 43.3a, 13/30 | 13.3, 2/15 | 64.3a, 18/28 | 82.1, 23/28 | 42.1, 8/19 | 17.6, 3/17 | |
| Biologic-exposed | 43.9a, 18/41 | 39.0a, 16/41 | 4.3a, 1/23 | 10.0, 1/10 | 50.0a, 14/28 | 60.7, 17/28 | 21.4, 3/14 | 46.2, 6/13 | |
Values are %, n/n.
Abbreviations: CD, Crohn’s disease; CRM, clinical remission; CRS, clinical response; MH, mucosal healing; SRM, steroid-free remission; UC, ulcerative colitis; VDZ, vedolizumab.
aBiologic-naïve vs biologic-exposed, P < .05.